ArticleCancer immunology, immunotherapy : CII2008
Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.
Article in Cancer immunology, immunotherapy : CII, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 99 citations in OpenAlex.
- Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.Cancer immunology, immunotherapy : CII · 2013Trial
- Targeting Myeloid-Derived Suppressor Cells via Dual-Antibody Fluorescent Nanodiamond Conjugate.Nanomaterials (Basel, Switzerland) · 2024Article
- Targeting myeloid-derived suppressor cells by inhibiting hypoxia-inducible factor 1α could improve tumor progression.Annals of medicine and surgery (2012) · 2024Article
- Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response.Science advances · 2023Article
- Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets.Exploration of targeted anti-tumor therapy · 2022Review
- Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.Frontiers in immunology · 2021Article
- Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma.PloS one · 2020Article
- Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment.OncoTargets and therapy · 2019Article
- Interplay between immune cells in lung cancer: beyond T lymphocytes.Translational lung cancer research · 2018Article
- Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer.Cancer immunology, immunotherapy : CII · 2018Observational
- Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients.Oncology letters · 2018Article
- The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer.Frontiers in immunology · 2018Review
- CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1Oncotarget · 2017Article
- Prostaglandin E Receptor EP4 expression, survival and pattern of recurrence in locally advanced NSCLC.Lung cancer (Amsterdam, Netherlands) · 2016Article
- Identification of CD4Biomedical reports · 2016Article
- The immunobiology of myeloid-derived suppressor cells in cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.The Journal of clinical investigation · 2015Review
- Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth.Oncoimmunology · 2015Article
- Myeloid-derived suppressor cells: paradoxical roles in infection and immunity.Journal of innate immunity · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAdvanced non-small cell lung cancer (NSCLC) remains an incurable disease. Immunotherapies that activate patients' T cells against resident tumor cells are being developed; however, these approaches may not be effective in NSCLC patients due to tumor-induced immune suppression. A major cause of immune suppression is myeloid-derived suppressor cells (MDSC). Because of the strategic role of CD4(+) T lymphocytes in the activation of cytotoxic CD8(+) T cells and immune memory, we are developing cell-based vaccines that activate tumor-specific CD4(+) T cells in the presence of MDSC. The vaccines are NSCLC cell lines transfected with costimulatory (CD80) plus major histocompatibility complex class II (MHC II) genes that are syngeneic to the recipient. The absence of invariant chain promotes the presentation of endogenously synthesized tumor antigens, and the activation of MHC II-restricted, tumor-antigen-specific CD4(+) T cells.
methodsPotential vaccine efficacy was tested in vitro by priming and boosting peripheral blood mononuclear cells from ten NSCLC patients who had varying levels of MDSC. CD4(+) T cell activation was quantified by measuring Type 1 and Type 2 cytokine release.
resultsThe vaccines activated CD4(+) T cells from all ten patients, despite the presence of CD33(+)CD11b(+) MDSC. Activated CD4(+) T cells were specific for NSCLC and did not cross-react with tumor cells derived from non-lung tissue or normal lung fibroblasts.
conclusionsThe NSCLC vaccines activate tumor-specific CD4(+) T cells in the presence of potent immune suppression, and may be useful for the treatment of patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.